Viral Vector Manufacturing Facility Pty Ltd (VVMF) announces its participation at the Cell & Gene Meeting on the Mesa 2025, October 6-8 2025, at the Arizona Biltmore Hotel, Phoenix, AZ, USA.
VVMF Head of Business Development and Partnerships, Anita van der Meer, will be available to discuss VVMF’s expertise in process development, viral vector manufacturing and the wrap-around services to leverage the advantages of the Australian biotechnology ecosystem.
VVMF’s Anita van der Meer shared, “The Meeting on the Mesa is an opportunity to connect and build new relationships within the global Cell & Gene therapy sector. We are excited to showcase VVMF’s advanced capabilities in lentiviral (rLV) and adeno-associated viral (rAAV) vector process development and manufacturing”.
Committed to supporting biotech and pharmaceutical companies, VVMF delivers high-quality viral vector solutions tailored to their research, clinical, and commercial needs. Backed by leading scientific and clinical expertise, VVMF provides a strategic advantage- further strengthened by Australia’s 43.5% R&D tax incentive for eligible companies.
Schedule a meeting via the meeting’s one-on-one partnering platform or contact us at info@vvmf.com.au to explore how VVMF can be your trusted partner in advancing cell and gene therapies.
Unlocking the future of medicine – with strong connections built at the Cell & Gene Meeting on the Mesa.